Erik Otto reports 6.3% Chemomab (CMMB) ADS stake in Schedule 13G/A

Rhea-AI Filing Summary

Chemomab Therapeutics Ltd. disclosed that individual investor Erik Otto, a Canadian citizen, has filed an amended Schedule 13G reporting a significant ownership stake in the company’s American Depositary Shares (ADSs).

Otto reports beneficial ownership of 385,000 ADSs, representing 6.3% of Chemomab’s ADSs, based on 6,155,117 ADSs outstanding as of November 20, 2025, as provided by the company. He has sole voting and sole dispositive power over all of these ADSs, meaning he alone can vote and decide when to sell them.

The filing is made on Schedule 13G/A, which is typically used for passive investors. Otto certifies that the securities were not acquired and are not held for the purpose of changing or influencing control of Chemomab, and are not held in connection with any control-seeking transaction.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 2)

Chemomab Therapeutics Ltd.

(Name of Issuer)

American Depository Shares, each of which represent twenty ordinary shares, no par value

(Title of Class of Securities)

36322Q107

(CUSIP Number)

02/10/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 36322Q107

1

Names of Reporting Persons

Otto Erik

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

CANADA (FEDERAL LEVEL)

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 385,000.00
6	Shared Voting Power
7	Sole Dispositive Power 385,000.00
8	Shared Dispositive Power

9

Aggregate Amount Beneficially Owned by Each Reporting Person

385,000.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.3 %

12

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person: *Percent of class represented by Row (11) based on 6,155,117 ADSs outstanding as of November 20th, 2025 (As provided by the Issuer)

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Chemomab Therapeutics Ltd.
(b)	Address of issuer's principal executive offices: KIRYAT ATIDIM, BUILDING 7, TEL AVIV, ISRAEL, 6158101
Item 2.
(a)	Name of person filing: Erik Otto
(b)	Address or principal business office or, if none, residence: 144 West Oakview Place, San Antonio, TX 78209
(c)	Citizenship: Canada
(d)	Title of class of securities: American Depository Shares, each of which represent twenty ordinary shares, no par value
(e)	CUSIP No.: 36322Q107
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 385,000
(b)	Percent of class: 6.3%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 385,000
	(ii) Shared power to vote or to direct the vote:
	(iii) Sole power to dispose or to direct the disposition of: 385,000
	(iv) Shared power to dispose or to direct the disposition of:
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Otto Erik

Signature:	Erik Otto
Name/Title:	Individual
Date:	02/10/2026

FAQ

What stake in Chemomab Therapeutics (CMMB) does Erik Otto report?

Erik Otto reports beneficial ownership of 385,000 Chemomab ADSs, representing 6.3% of the class. This percentage is calculated using 6,155,117 ADSs outstanding as of November 20, 2025, as stated by Chemomab.

What type of filing did Erik Otto submit for Chemomab (CMMB)?

Erik Otto submitted an amended Schedule 13G/A, a beneficial ownership report for holders of more than 5% of a class. This form is generally used by investors who characterize themselves as passive rather than seeking control.

Does Erik Otto have voting and dispositive power over his Chemomab (CMMB) shares?

Yes. The filing states he has sole voting power and sole dispositive power over 385,000 ADSs. He reports no shared voting or shared dispositive power with any other person or entity for this Chemomab position.

How was the 6.3% ownership in Chemomab (CMMB) calculated?

The reported 6.3% ownership is based on Otto’s 385,000 ADSs compared against 6,155,117 ADSs outstanding as of November 20, 2025. That outstanding share figure was provided by Chemomab and cited directly in the ownership calculation.

Is Erik Otto seeking to influence control of Chemomab Therapeutics (CMMB)?

According to the certification, Otto states the ADSs were not acquired and are not held to change or influence control of Chemomab. He also notes the holdings are not part of any transaction aimed at obtaining control of the issuer.

What class of Chemomab (CMMB) securities does this Schedule 13G/A cover?

The filing covers American Depositary Shares (ADSs) of Chemomab Therapeutics Ltd. Each ADS represents twenty ordinary shares with no par value, as specified in the ownership disclosure section of the document.